Outsourcing High Potent Oral Solid Dose Late-Stage Development: CDMO Insights

Join us at this webinar to discover outsourcing options for highly potent oral solid dose therapies, and learn how CDMOs can transfer, handle and deliver their product to clinic and to market.

The development and manufacture of drug products containing highly potent active pharmaceutical ingredients (HPAPIs) is in growing in demand. Recent data suggest that between 2023 and 2030, the small molecule drug discovery market will register a compound annual growth rate (CAGR) of around eight percent. This is particularly relevant in the field of oncology, which accounts for around 35 percent of small molecule drug candidates, around half of which contain HPAPIs.

The development of targeted therapies and precision medicines has revolutionized cancer treatment, resulting in more effective and potentially less toxic therapeutic options for patients. Furthermore, regulatory agencies including the US Food and Drug Administration (FDA) have implemented accelerated approval pathways, fostering innovation and promoting faster commercialization of novel oncology drugs. In this dynamic landscape, the role of CDMOs becomes even more critical.

In this webinar, experts will explain what the gold standard is for an outsourcing partner for high potent oral solid dose therapies, the necessary equipment and facilities, and how to maintain flexibility in a multi-product facility. They will also discuss a real-world case study, highlighting the importance of selecting the right CDMO for high potent outsourcing.